Podcasts about pain therapeutics

DEEP DIVE into (LDN) Low Dose Naltrexone with Sebastion Denison, RPh, Andy Komuves, RPh, & Joe Bertrand, RPhLow Dose Naltrexone (LDN) Clearly from the adjectives it's a “non standard” dosage from what naltrexone was originally intended. But why?LDN is a method (with EXTENSIVE data) of finding benefits to healing from certain issues that have often left people hopeless. Weight management, nerve damage, palsy, autoimmune thyroid disorders, cancer, chronic fatigue syndrome, chronic pain,Crohn's diease, fibromyalgia, PTSD, multiple sclerosis, myalgic encephalomyelitis.The GCP welcomes three experts and Clinical Compounding Pharmacists to share with you their knowledge and experience in helping people find comfort and happiness again in their lives! Sebastion Denison, RPh, Andy Komuves, RPh, & Joe Bertrand, RPh join Ken & Eric to discuss the hype and evidence around LDN.REFERENCES https://a4pc.org/  https://www.pccarx.com/Resources/FindACompounderhttps://www.achc.org/compounding-pharmacy/ https://ldnresearchtrust.org/  https://ldnresearchtrust.org/2024_LDN_Guideshttps://ldnresearchtrust.org/sites/default/files/2024-02/Dosing-Guide-2024_0.pdf  current dosing recommendations   https://www.jpsmjournal.com/article/S0885-3924%2803%2900139-8/fulltext  Ultra low dose early info Purdue had Oxycontin and the combination was used clinically and was pursued, then Oxytrex was the trade name-2005 phase 3 trials,  by a company Pain Therapeutics-but did not launch or fully launchTROXYCA® ER is a Pfizer product in 2016 (higher doses)https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207621s004lbl.pdf 

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.12.12.520139v1?rss=1 Authors: Liu, P. W., Zhang, H., Werley, C. A., Pichler, M., Ryan, S., Lewarch, C., Jacques, J., Grooms, J., Ferrante, J., Li, G., Zhang, D., Bremmer, N., Barnett, A., Chantre, R., Elder, A. E., Cohen, A. E., Williams, L. A., Dempsey, G. T., McManus, O. B. Abstract: Chronic pain associated with osteoarthritis (OA) remains an intractable problem with few effective treatment options. New approaches are needed to model the disease biology and to drive discovery of therapeutics. Here, we present an in vitro model of OA pain, where dorsal root ganglion (DRG) sensory neurons were sensitized by a defined mixture of disease-relevant inflammatory mediators, here called Sensitizing PAin Reagent Composition or SPARC. OA-SPARC components showed synergistic or additive effects when applied in combination and induced pain phenotypes in vivo. To measure the effect of OA-SPARC on neural firing in a scalable format for drug discovery, we used a custom system for high throughput all-optical electrophysiology. This system enabled light-based membrane voltage recordings from hundreds of neurons in parallel with single cell resolution and a throughput of up to 500,000 neurons per day, with patch clamp-like single action potential resolution. A computational framework was developed to construct a multiparameter OA-SPARC neuronal phenotype and to quantitatively assess phenotype reversal by candidate pharmacology with different mechanisms of action. We screened ~3000 approved drugs and mechanistically focused compounds, yielding data from over 1.2 million individual neurons with detailed assessment of both functional OA-SPARC phenotype rescue and orthogonal 'off-target' effects. Analysis of confirmed hits revealed diverse potential analgesic mechanisms including well-known ion channel modulators as well as less characterized mechanisms including MEK inhibitors and tyrosine kinase modulators, providing validation of the platform for pain drug discovery. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

Therapy of pain is a challenge and requires special approaches. This course, as part of the Pain Educators Forum (PEF), will build on information provided in other PEF sessions and focus on the prevalence and impact of unrelieved pain, pathogenesis, and treatments of pain. Participants will learn about approaches and advances in therapy of common acute and chronic pain syndromes, and evidence based recommendations for pharmacotherapy of pain will be provided. Pain Therapeutics examines current trends in pain relief, which can be implemented into practice as soon as attendees return to work.

Pain therapy is a challenge and requires special approaches. This course, as part of the Pain Educators Forum (PEF), will build on information provided in other PEF sessions and focus on the prevalence and impact of unrelieved pain, pathogenesis, and treatments of pain. Participants will learn about approaches and advances in therapy of common acute and chronic pain syndromes, and evidence based recommendations for pharmacotherapy of pain will be provided. Pain Therapeutics examines current trends in pain relief, which can be implemented into practice as soon as attendees return to work. (Recorded at PAINWeek 2018)

Solid slips and Pain Therapeutics loses it. Also light bulbs for your ears and why Nat hates doctors.

Today in FirstWord:

Today in FirstWord:

Therapy of pain is a challenge and requires special approaches. This course, as part of the Pain Educators Forum, will build on information provided in other sessions and focus on the prevalence and impact of unrelieved pain, pathogenesis, and treatments of pain. Participants will learn about approaches and advances in therapy of common acute and chronic pain syndromes. Evidence based recommendations for pharmacotherapy of pain will be provided. Pain therapeutics will examine current trends in pain relief that can be implemented into practice.

1) A clinical pathologic study of depressive symptoms and cognitive decline in old age and 2) Topic of the month: Contemporary alternative medicine therapies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Robert S. Wilson about his paper on depressive symptoms and cognitive decline in old age. Dr. Adam Numis is reading our e-Pearl of the week about ictal syncope. In the next part of the podcast Dr. Rebecca Wells interviews Dr. Tieraona Low Dog about complementary alternative medicine therapies using supplements for treatment of headaches. The participants had nothing to disclose except Drs. Burns, Wilson and Numis. Dr. Jeff Burns serves on the editorial board for Journal of Alzheimer's Disease; receives royalties for the publications of Early diagnosis and treatment of mild cognitive impairment and Dementia: An atlas of investigation and diagnosis; is a consultant for PRA International and receives research support from the NIH, Alzheimer's Drug Discovery Foundation, Elan, Janssen Pharmaceuticals Inc., Wyeth, Pfizer Inc, Novartis Pharmaceuticals Ltd, Danone, Avid Radiopharmaceuticals, Merck Serono and for clinical trials. Dr. Wilson serves as a Consulting Editor of Aging, Neuropsychology and Cognition, Psychology and Aging, and Neuropsychology; is a consultant for Pain Therapeutics, Inc.; and receives research support from the NIH. Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section.

Edward Burns, M.D., executive dean, presents opening remarks at "Licensing Einstein Technology: The Inside Story: Metastatic Melanoma & Pain Therapeutics." Presenters and panelists describe the path of a novel melanoma technology invented at Einstein — from its beginnings in the lab to its current stage in clinical trials sponsored by Pain Therapeutics, Inc. (September 24, 2009)

Ekaterina Dadachova, Ph.D., the Sylvia & Robert S. Olnick Faculty Scholar in Cancer Research, discusses the technology she invented with Arturo Casadevall, M.D., Ph.D., and Joshua Nosanchuk, M.D. The technology, radioimmunotherapy of metastatic melanoma with radiolabeled melanin-binding antibodies, was invented at Einstein and is now in clinical trials sponsored by Pain Therapeutics. (September 24, 2009)

Panelists discuss an Einstein innovation moving from "bench to bedside." Einstein-invented technology intended to treat metastatic melanoma is in clinical trials by Pain Therapeutics, Inc. Panelists include: Ekaterina Dadachova, Ph.D., the Sylvia & Robert S. Olnick Faculty Scholar in Cancer Research; John Harb, director of the office of biotechnology; and Remi Barbier,CEO of Pain Therapeutics, Inc. (September 24, 2009)